September, 2024, Eutropics Pharmaceuticals is pleased to announce an extension of its long-standing research collaboration with the University of Texas MD Anderson Cancer Center, focused on advancing the PRIMAB™ functional biomarker platform in Acute Myeloid Leukemia (AML). The renewed MTA agreement builds upon more than a decade of joint research aimed at translating insights into apoptosis regulation and drug response into actionable diagnostic tools for clinical application. The ongoing studies are led by Dr. Bing Carter, of MD Anderson’s AML research group and a leader in AML biology related to therapeutic development. Together with Eutropics, Dr. Carter’s team is working to refine and clinically validate functional measures that can help guide therapeutic choices and improve patient outcomes.“This collaboration with MD Anderson has been foundational in the evolution of the PRIMAB platform,” said Eutropics clinical science advisor Duncan Whitney . “Eutropics will do well to continue towards developing new tests with Dr. Carter as we advance toward broader clinical integration of our diagnostics in AML.”
